Exosens Shares Drop Over 5% Testing a Key Technical Threshold at €61
Exosens drops more than 5% this Friday mid-session, trading at €61.00, while the CAC 40 is up by 0.79% at the same time. This downturn brings the stock close to its 50-day moving average and emphasizes a notable weekly decline of -6.44% over seven days.
Exosens stock is priced at €61.00, nearly touching its 50-day moving average (€61.15), a level that acts as a pivotal zone in the short term. A sustained breach below this threshold could pave the way towards the support identified at €57.50, close to the lower boundary of the Bollinger Bands (€56.33). The price is currently in the lower part of these bands, about 26% of the total amplitude, indicating significant selling pressure in recent sessions. The RSI, at 52, remains in a neutral zone and does not indicate overselling at this stage.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
While the past week has weighed on the stock, the medium and long-term trajectory remains distinctly bullish. Over three months, Exosens has gained nearly 8%, and the increase reaches 101.3% over a year, marking a remarkable stock market journey since the company's debut. The price is significantly above the 200-day moving average (€48.61), a gap of more than 25% that reflects the strength of the underlying trend. The next key event for shareholders will be the release of the first quarter 2026 results, expected on April 27. This milestone could be a crucial catalyst for the stock's direction in the coming weeks. The general meeting is scheduled for May 22. Until then, the stock's low correlation with the market, indicated by a beta of 0.12, means that Exosens' movements are largely driven by company-specific factors rather than the general trend of the indices.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
